# A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus

> **NCT03334058** · PHASE2 · COMPLETED · sponsor: **argenx** · enrollment: 34 (actual)

## Conditions studied

- Pemphigus Vulgaris
- Pemphigus Foliaceus

## Interventions

- **DRUG:** ARGX-113

## Key facts

- **NCT ID:** NCT03334058
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-18
- **Primary completion:** 2020-10-28
- **Final completion:** 2020-10-28
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2020-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03334058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03334058, "A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03334058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*